Natural and Synthetic Cannabinoids: What They Are and How They Might Be Used as Medicine
A review of patents from 2003-2007 cataloged methods for isolating, purifying, and synthesizing cannabinoids and their potential therapeutic applications beyond the FDA-approved uses of dronabinol.
Quick Facts
What This Study Found
This review covered the landscape of naturally occurring cannabinoids (phytocannabinoids) and their synthetic analogs, focusing on patents filed between 2003 and 2007.
The review noted that while psychotropic effects of cannabis are mainly attributed to THC, cannabinoids also affect the cardiovascular, immune, and endocrine systems through interactions with CB1 and CB2 receptors.
The FDA had approved synthetic THC (dronabinol/Marinol) in 1985 for chemotherapy-related nausea and in 1992 as an appetite stimulant for AIDS patients. The patent literature from 2003-2007 showed expanded research interest in isolation methods, purification techniques, chemical synthesis routes, and new therapeutic applications.
Key Numbers
Marinol (synthetic THC) was FDA-approved in 1985 for chemotherapy nausea and in 1992 for AIDS-related appetite stimulation. Patent review covered 2003-2007.
How They Did This
Patent review covering methods for cannabis compound isolation, chromatographic purification, synthesis, and therapeutic applications described in patents from 2003 to 2007.
Why This Research Matters
This review captured the state of cannabinoid pharmaceutical development at a pivotal moment, documenting the expanding commercial and research interest in cannabis-derived medicines.
The Bigger Picture
The patent landscape in 2003-2007 foreshadowed the expansion of cannabinoid-based pharmaceuticals that would follow, including the eventual FDA approval of CBD (Epidiolex) in 2018.
What This Study Doesn't Tell Us
Patent reviews describe what companies and researchers claim, not what has been clinically validated. Many patented compounds and methods never reach clinical use.
Questions This Raises
- ?Which of the patented therapeutic applications would eventually be validated in clinical trials?
- ?How would the regulatory landscape for cannabinoid medicines evolve?
Trust & Context
- Key Stat:
- Dronabinol was FDA-approved in 1985 and 1992; patent activity showed expanding therapeutic interest
- Evidence Grade:
- Patent review providing a landscape overview rather than clinical evidence. Patents describe potential applications, not proven treatments.
- Study Age:
- Published in 2009. The cannabinoid pharmaceutical landscape has changed dramatically since then, with CBD (Epidiolex) receiving FDA approval in 2018 and numerous other products in development.
- Original Title:
- Naturally occurring and related synthetic cannabinoids and their potential therapeutic applications.
- Published In:
- Recent patents on CNS drug discovery, 4(2), 112-36 (2009)
- Authors:
- Galal, Ahmed M, Slade, Desmond(2), Gul, Waseem, El-Alfy, Abir T, Ferreira, Daneel, Elsohly, Mahmoud A
- Database ID:
- RTHC-00354
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is the difference between natural and synthetic cannabinoids?
Natural cannabinoids (phytocannabinoids) come from the cannabis plant. Synthetic cannabinoids are created in laboratories to mimic or modify the structure and effects of natural compounds, allowing for standardized dosing and potentially improved therapeutic properties.
Why was there so much patent activity around cannabinoids?
The therapeutic potential of cannabinoids was increasingly recognized, but challenges with plant-derived products (variability, legal issues) drove interest in synthesis and purification methods that could produce pharmaceutical-grade compounds.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00354APA
Galal, Ahmed M; Slade, Desmond; Gul, Waseem; El-Alfy, Abir T; Ferreira, Daneel; Elsohly, Mahmoud A. (2009). Naturally occurring and related synthetic cannabinoids and their potential therapeutic applications.. Recent patents on CNS drug discovery, 4(2), 112-36.
MLA
Galal, Ahmed M, et al. "Naturally occurring and related synthetic cannabinoids and their potential therapeutic applications.." Recent patents on CNS drug discovery, 2009.
RethinkTHC
RethinkTHC Research Database. "Naturally occurring and related synthetic cannabinoids and t..." RTHC-00354. Retrieved from https://rethinkthc.com/research/galal-2009-naturally-occurring-and-related
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.